tbuckley/cabot-search huggingface dataset:
AB0978 ASSOCIATION OF SLEEP QUALITY WITH DISEASE ACTIVITY, INFLAMMATION, MOBILITY, AND FUNCTION AMONG PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Authors: I. P. Lee, F. Y. Wu, C. F. Su, S. H. Lin, Y. S. Chang
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Inflammation and ankylosis of the axial skeleton are two major features of axial spondyloarthritis (axSpA), which cause midnight pain and immobility of back, respectively. Both features may lead to sleep problem. Nevertheless, which of the two features influence sleep most is less studied. Moreover, there are many disease activity measurements, including BASDAI, ASDAS, ESR and CRP, among these measurements, which one could best predict sleep disturbance are still unknown. <h3>Objectives</h3> This pilot study aimed to discover the association between different measurements of axSpA and sleep disturbance. <h3>Methods</h3> This cross-sectional study recruited patients with axSpA from the rheumatology clinic in the Shuang-Ho hospital from 2018 to 2020. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality together with other clinical measurements, including BASDAI, ESR, CRP and ASDAS-CRP for disease activity, BASMI for mobility and BASFI for function. The features associated with poor sleep quality (PSQI &gt; 5) were identified. All the domains of sleep disturbance were compared between patients with different level of disease activity classified by each activity measurement. <h3>Results</h3> This cross-sectional study recruited 322 patients with axSpA, among them 72% were male, and the mean age was 42 years. There were 249 (77.3%) patients had poor sleep quality (PSQI&gt;5). Poor sleepers had significantly higher BASDAI, ASDAS-CRP and BASFI, while there was no significant difference in sex, age, ESR, CRP and BASMI. Patients with higher BASDAI had significantly poorer sleep quality in almost all domains of PSQI (figure 1A), while higher level of ESR or CRP could not discriminate poor sleeper in every domain of PSQI (figure 1C,1D). ASDAS-CRP had a moderate discriminability, which was believed brought by the integrated components of BASDAI in the index. <h3>Conclusion</h3> Lots of patients (77.3%) with axSpA were poor sleeper, which is worthy note in clinical care. Mobility seems to have less influence on sleep than disease activity. Although BASDAI was believed too subjective as a disease activity index, it performed the best to discriminate poorer sleep quality in almost all domains of sleep. Although ESR and CRP were more objective disease activity markers of axSpA and have better relevance to the MRI-demonstrated inflammation, both the inflammatory markers had no value in the care of sleep in axSpA patients surprisingly. In conclusion, BASDAI still had value in axSpA care, and the elements of BASDAI make ASDAS a more comprehensive index than ESR or CRP alone. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1123 EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH PSORIASIS
Authors: Q. Y. Su, B. R. Zhao, H. J. Gao, S. C. Sun, J. Luo, Q. Yu, P. F. He, X. Li, S. X. Zhang
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Psoriasis is a chronic, multisystem inflammatory disease with predominantly skin and joint involvement. The interleukin-(IL-)17 axis plays a vital role in the development of psoriasis. Secukinumab (Cosentyx) is a fully human monoclonal antibody that selectively targets IL-17A for the treatment of adult patients with psoriasis<sup>[1]</sup>. <h3>Objectives</h3> This study aimed to systematically evaluate the efficacy and safety of secukinumab therapy in psoriasis. <h3>Methods</h3> Eight databases (PubMed, Web of Science, Embase, Cochrane Library, Web of Knowledge, MEDLINE, Clinical Trials.gov, and FDA.gov) were searched for studies on secukinumab treatment of psoriasis published from the date of establishment of the database to January 3, 2022. A random effect model was used to conduct a meta-analysis of the efficacy and safety of abatacept in patients with RA using (Stata 12.0). <h3>Results</h3> A total of 27 studies with a total of 4470 patients were included. After receiving secukinumab therapy for 12 weeks, The response rate of PASI 75 was 82.2% (95% CI 0.766–0.879,p&lt;0.01), PASI 90 was 66.3%(95% CI 0.609–0.718,p&lt;0.01), and PASI 100 was 42% (95% CI 0.343–0.497,p&lt;0.01). The results showed that more than 80% of patients achieved skin lesion removal in 12 weeks. Considering PGA 0/1 as the secondary endpoint. The percentage of patients who achieved a PGA score of 0 or 1 was 72.3% at 12 weeks (95% CI 0.658–0.788,p=0.005). As for the safety, the incidence of adverse events was 63.7%. Infection is the main adverse effects, with rates of 19.4%. Most of the adverse events were mild and recovered quickly after discontinuation. (Figure 1) <h3>Conclusion</h3> Secukinumab is effective in patients with psoriasis and is generally well tolerated, and thus represents a useful treatment alternative to TNFi and other bDMARDs in adult patients with psoriasis. <h3>Reference</h3> [1]Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483-94. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1057 LUNG ULTRASONOGRAPHY AS A SCREENING TOOL FOR INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW
Authors: A. Alunno, S. Bellando Randone, E. Pintus, N. Piccini, J. Schoones, M. Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In rheumatoid arthritis (RA), interstitial lung disease (ILD) is a frequent pulmonary manifestation which is responsible for a high morbidity and mortality. Chest high resolution computed tomography (HRCT) is the imaging gold standard for the diagnosis and characterisation of ILD. Recently, the use of lung ultrasonography (US) has been suggested as a valid, less invasive and radiation-free tool in the pulmonary screening process. <h3>Objectives</h3> To review the reliability of lung US as a screening tool for the diagnosis of ILD in RA patients. <h3>Methods</h3> A systematic literature search in several databases was conducted following the PICO framework on July 2022. Two researchers independently screened abstracts and titles, and full texts were subsequently reviewed to determine eligibility (original research articles enrolling adult RA patients undergoing lung US and HRCT). Data from eligible articles were extracted and risk of bias (RoB) was assessed with validated tools. Owing to extensive interstudy heterogeneity, narrative summaries had to be used to present the data. <h3>Results</h3> Out of 690 retrieved papers, only 7 were eligible and only 5 of them enrolled a control group (Table 1). All studies had a cross-sectional design and no follow-up data were available. Although all studies relied on the US identification of B-lines, the number of intercostal spaces assessed as well as the threshold/score to classify the findings as ILD or no-ILD varied across studies. Furthermore, some studies also focused on the irregularities of the pleural line. The sensitivity of lung US ranged between 62.2 and 97.1% while specificity ranged between 89 and 100%. However, the studies' heterogeneity did not allow any comparison. In RA patients with neither respiratory symptoms nor previous ILD diagnosis, the concordance in identifying pathological findings between US and HRCT ranged between 90 and 100%. <h3>Conclusion</h3> Our Systematic Literature Review shows that lung US may have a role as screening tool for ILD in RA and also in asymptomatic patients. The implementation of the routine use of lung US in RA might allow an early identification and a prompt treatment of RA-ILD patients as well. However, the harmonization of US findings is required to allow either for the comparison of research studies and for a broad implementation of lung US in clinical practice. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1836-HPR SERUM LEVEL OF VITAMIN D IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS CORRELATION WITH BONE MINERAL DENSITY AND THE DISEASE ACTIVITY
Authors: S. Shevchuk, L. Denyshchych, L. Marynych
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Decrease in vitamin D levels in patients with systemic lupus erythematosus (SLE) arouses particular interest. Vitamin D levels and their correlation with bone mineral density (BMD) loss are still seen as contradictory. <h3>Objectives</h3> To study serum vitamin D levels in SLE women and to estimate their correlation with BMD and disease activity. <h3>Methods</h3> 101 SLE women and 30 individuals in a control group participated in the study. The activity of SLE was evaluated by SLEDAI. The average age of patients was 47.12 ± 0.14 years, in the control group it was 46.17 ± 0.12. Serum levels of C-reactive protein (CRP) and 25-hydroxyvitamin D (25(ОН)D) were measured in all participants. Changes in BMD of the lumbar spine and hip were determined by dual-energy X-ray densitometry. <h3>Results</h3> In patients with SLE, the average level of 25(ОН)D equalled 14.6 ± 1.19 ng/ml, and in the individuals from the control group, it was 1.9 times higher, constituting 24.7 ± 1.32 ng/ml. In SLE women with normal BMD (T score &gt; -1.0 SD) vitamin D deficiency (&lt; 20 ng/ml) was detected in 18.3%. In the group with osteopenia (T-score from -1.0 to -2.5 SD), the proportion of individuals with vitamin D deficiency has increased to 26.7%. In women with osteoporosis (T-score ≤ -2.5 SD), vitamin D deficiency was found in 63.9%. In the group of patients with the maximum CRP level there were only 10% of persons with the optimal (&gt; 30 ng/ml) 25(ОН)D level, 40% had insufficiency (20-30 ng/ml), while deficiency (&lt; 20 ng/ml) was detected in every second patient. Among patients with optimal CRP levels, only every fourth person was diagnosed with vitamin D deficiency, 10% of the individuals had vitamin D insufficiency, while 65% had optimal vitamin D levels. Decrease in vitamin D level was closely associated with SLE activity revealed by SLEDAI (r = -0.44; р &lt; 0.05). <h3>Conclusion</h3> The average vitamin D level in SLE women is likely to be lower than that in the control group. Decrease in vitamin D levels was associated with BMD loss and high inflammatory process as well as the disease activity according to CRP and SLEDAI. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0778 HISTOPATHOLOGIC FEATURES AND CLINICAL OUTCOMES IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Authors: E. Takamasu, N. Yokogawa, I. Takahashi, K. Shimada
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The main histological features of eosinophilic granulomatosis with polyangiitis (EGPA) are tissue eosinophilia (TE), small-vessel vasculitis (SVV), and extravascular granuloma. However, the relationship between these pathological findings and treatment response is not known. <h3>Objectives</h3> To explore the associations between pathological features of TE or SVV and the clinical parameters and treatment response in EGPA patients. <h3>Methods</h3> This is a single-center, retrospective, cohort study. Subjects who met the following were included for analysis: 1) those who fulfilled the 1990 ACR criteria and/or the 2012 revised CHCC criteria and/or the ACR/EULAR 2022 criteria, 2) those who were treated for at least 2 years in our hospital since 1/1/2010, 3) those who had undergone tissue biopsy at any site during their initial diagnostic workup. All available slides of biopsies were reviewed by a blinded pathologist expertise with vasculitis. Based on the EULAR recommendations, remission was defined as the absence of vasculitis activity (BVAS=0) with daily doses of prednisolone &lt;=7.5mg after 2 years of treatment and refractory disease was defined as failure to attain remission. <h3>Results</h3> Among 37 patients diagnosed with EGPA, 30 patients were included. Total 84 biopsies (muscle 36, skin 15, nose 9, colon 8, stomach/duodenum 4, nerve 4, kidney 3, lung 2, heart 1, small intestine 1, and temporal artery 1) were reviewed. SVV, TE, and extravascular granuloma were found in 17 (56.5 %) patients, 16 (53.3 %) patients and 3 (10 %) patients, respectively. (Fig.1) SVV was associated with refractory disease (47.1 % vs 0 %, p=0.04). TE was associated with skin lesions (56.2 % vs 14.3%, p = 0.021) and inversely associated with severe peripheral neuropathy (43.8 % vs 85.8 %, p = 0.021). (Table.1) ANCA was present in 11 (36.7 %) patients. ANCA was not associated with refractory diseases (ANCA positive 36.3% vs ANCA negative 21.1%, p=0.31) <h3>Conclusion</h3> In EGPA, pathological evidence of SVV may be better predict poor treatment response than ANCA positivity. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0999 RELIABILITY OF INFLAMMATORY BACK PAIN CRITERIA AS A TOOL FOR DIFFERENTIATION BETWEEN INFLAMMATORY AND MECHANICAL BACK PAIN AMONG EGYPTIAN PATIENTS
Authors: M. A. Mortada, N. Ehab, E. Elshahawy, S. Elnaggar
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Inflammatory back pain (IBP) is a key symptom of axial spondyloarthritis (AxSpA). Most items of the IBP criteria are subjective and liable to change depending on the patient's expression. (1) <h3>Objectives</h3> Assessment of the sensitivity, specificity, and reliability of IBP parameters and sets in patients with AxSpA. <h3>Methods</h3> This case-control study was conducted on 2 groups: the first group included 103 patients with AxSpA, and the other group included 103 patients with chronic mechanical back pain. A standardized questionnaire, addressing all items included in Calin, Berlin, and ASAS criteria sets, was applied by 2 rheumatologists (one senior and one junior) to both groups. The sensitivity, specificity, and reliability of the 3 sets and individual parameters were assessed. <h3>Results</h3> Morning stiffness &gt; 30 minutes was the most specific parameter (81%), while the insidious onset was the most sensitive (98%). Calin set was the most sensitive set (88.1%), but it had the least specificity (60%). Adding the item of Morning stiffness &gt; 30 minutes to Calin criteria resulted in improving the specificity of Calin criteria to 81%. Reliability of all parameters and the 3 sets showed moderate agreement (kappa 0.422–0.588) except for Morning stiffness &gt; 30 minutes which showed good agreement (kappa 0.736) and night pain which showed fair agreement (kappa 0.388) (Table 1). <h3>Conclusion</h3> Most IBP parameters and criteria have moderate reliability and average sensitivity and specificity. There may be a need for an objective tool to differentiate between inflammatory and mechanical back pain. <h3>Reference</h3> [1]Poddubnyy D, Callhoff J, Spiller I, Listing J, Braun J, Sieper J, Rudwaleit, M (2018) Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. RMD open, 4(2): e000825. http://dx.doi.org/10.1136/rmdopen-2018-000825 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Mohammed A Mortada Speakers bureau: NOVARTIS. SANDOS. EVA, Grant/research support from: EVA, NOHA EHAB: None declared, Eman Elshahawy: None declared, Safaa Elnaggar: None declared.
AB0083 CD14+CD90+ CELLS IN PERIVASCULAR AREAS OF RHEUMATOID ARTHRITIS SYNOVIAL TISSUES HAVE POTENTIAL TO DIFFERENTIATE INTO DENDRITIC CELLS
Authors: R. Kurose, T. Satoh, A. Kurose, Y. Ishibashi, Y. Wakai, T. Sasaki, K. Ishida, K. Ogasawara, T. Sawai
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> We have previously reported that CD14+ dendritic-shaped cells show a dendritic morphology under the electron microscopy and engage in a pseudoemperipolesis phenomenon with lymphocytes. CD14+ dendritic-shaped cells express CD90 in the perivascular areas of RA synovial tissues. <h3>Objectives</h3> To examine the differentiation potential of CD14+CD90+ cells into dendritic cells and their relationship to chronic inflammation in RA. <h3>Methods</h3> RA synovial tissues harvested at the time of joint surgeries were used after obtaining informed consent. The harvested tissues were cultured in vitro, and CD14+CD90+ cells were sorted using flow cytometry. Subsequently, the cells were divided into CD14+CD90+ and non-CD14+CD90+ cell groups and cultured in dendritic cell differentiation medium. The populations of cells expressing CD83 and HLA-DR were examined by flow cytometry to determine their differentiation potential into dendritic cells. <h3>Results</h3> At day 7 after dendritic cell differentiation culture, the group of CD14+CD90+ cells had a higher percentage of cells expressing CD83 and HLA-DR than the group of non-CD14+CD90+ cells. <h3>Conclusion</h3> CD14+ dendritic-shaped cells detected in RA synovial tissues are considered to be derived from CD14+CD90+ cells in the perivascular areas, which may be involved in RA inflammation as dendritic cells. <h3>References</h3> [1]Ochi T, Sawai T, Murakami K, Kamataki A, Uzuki M, Tomita T, et al. Nurse-like cells in rheumatoid arthritis: Formation of survival niches cooperating between the cell types. Mod Rheum 2018; 29: 1-5. [2]Kurose R, Satoh T, Kurose A, Satoh Y, Ishibashi Y, Wakai Y, et al. Association of CD90 expression by CD14+ dendritic-shaped cells in rheumatoid arthritis synovial tissue with chronic inflammation. ACR Open Rheumatology 2022; 0: 1-10. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1136 DISEASE-MODIFYING EFFECT AND LONG-TERM SAFETY DATA OF BELIMUMAB IN PATIENTS WITH SLE: A SINGLE CENTRE RETROSPECTIVE ANALYSIS
Authors: M. Okada, T. Nakai
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Disease modification is an important concept for minimizing disease activity with the fewest treatment-associated toxicities when managing SLE. Belimumab has been used as a maintenance therapy for SLE; however, data on its disease-modifying effects are scarce. <h3>Objectives</h3> Therefore, we aimed to investigate the disease-modifying effects of belimumab in SLE patients. <h3>Methods</h3> This single-centre retrospective cohort study included SLE patients treated with belimumab at our institution. We analysed the changes in flare-free ratio, lupus low disease activity state (LLDAS) achievement ratio, glucocorticoid dosage, SLICC/ACR damage index (SDI) score, and drug retention rate after belimumab initiation. <h3>Results</h3> Of the 567 patients with SLE followed up in our hospital, 95 used belimumab and to 92 were included in the study. Fifty-two weeks after initiating belimumab, the flare rate decreased (82.6% to 14.1%) (p&lt;0.01). At week 52 and day 1,000 after initiation of belimumab, &gt;70% and approximately 90% of the patients achieved LLDAS, respectively. Belimumab administration also significantly decreased glucocorticoid demands, and at the end of the study period, 68.5% of patients achieved prednisolone ≤5 mg/day and 22.8% achieved glucocorticoid discontinuation. Furthermore, most patients were free of SDI progression (week 52, ±95%; end of study period, almost 90%), and belimumab showed a high drug retention rate (week 52, 90%; day 1000 after initiation &gt;80%). <h3>Conclusion</h3> Most patients on belimumab achieved LLDAS, decreased flare rate and glucocorticoid demand, and a stable trend of SDI after its induction. Furthermore, belimumab had a high drug retention rate. Therefore, the introduction of belimumab may be a key element in disease modification. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Masato Okada Speakers bureau: Elli-Lilly, Janssen, Takehiro Nakai: None declared.
AB1027 CHARACTERISTICS OF UVEITIS IN SPONDYLOARTHRITIS IN A MULTICENTER STUDY IN MOROCCO
Authors: H. Arabi, A. Mougui, H. Sahimi, N. Takhrifa, S. Mouhcine, T. Harzy, F. Abourazzak, S. Janani, R. Bahiri, A. Bezza, I. El Ghozlani, R. Niamane, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Uveitis is the most common extra-articular manifestation of Spondyloarthritis (SpA). <h3>Objectives</h3> The aim of this study was to determine the prevalence of uveitis in patients with SpA in a multicenter series and to identify factors associated with its occurrence. <h3>Methods</h3> A multicenter descriptive analytical study, including patients followed for SpA in 8 rheumatology departments from 6 different regions in Morocco. All data were measured by standard instruments. Demographic, clinical, paraclinical and therapeutic data of the disease were collected. Disease activity was assessed by BASDAI and ASDAS-CRP scores. Data analysis was done by SPSS.20 software, the p significance level was set at 0.05. <h3>Results</h3> The study had included 700 patients followed for SpA, 54% of whom were men. The mean age at diagnosis was 40.42 + 14.19 years. The average diagnosis delay was 59.76 months. The percentage of patients who smoked was 15.6%. A family history of SpA was noted in 11.7%. SpA was non-radiographic in 14% of cases. Bilateral sacroiliitis was described in 49.4%. Coxitis was present in 32.5%. Juvenile SpA represented 15.5% of cases. The prevalence of HLA-B27 was 65.51%. Systemic involvement was dominated by uveitis (11.3%), it was unilateral in 59.5%, bilateral in 28.6% and tilted in 11.9%, anterior in 95.7%. Evolution of the uveitis was acute in 88.9% and chronic in 11.1%. The mean of BASDAI and ASDAS ware 4.42 ±1.67 and 3.19 ±1.24 respectively. The mean CRP and erythrocyte sedimentation rate (ESR) were 35.5 mg/l and 43.3mm respectively. The mean BASDAI was significantly higher in SpA with uveitis (p=0.025). Biological treatments, in particular tumor necrosis factor-α (TNF-α) inhibitors were more prescribed in patients with uveitis; 47.5% versus 30.9% in SpA without uveitis, with a significant difference (p=0.006). Uveitis was less present in SpA associated with inflammatory bowel disease (p=0.004). However, we did not find a significant association with gender (p=0.61), age at diagnosis (p=0.69), age of onset of symptoms (p=0.8), diagnostic delay (p=0, 58), smoking (p=0.06), clinical forms of SpA (p=0.71), coxitis (p=0.6), HLA B27 antigen (p=0.17), ESR (p=0.56), CRP (p=0.99) and ASDAS-CRP (p=0.51). <h3>Conclusion</h3> In our study, the prevalence of uveitis was 11.3%. Its presence was associated with a higher activity according to the BASDAI, and it was associated with a higher use of biological treatments. <h3>Reference</h3> [1]Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Therapeutic Advances in Musculoskeletal. 2020 Jan;12:1759720X2095173. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study
Authors: Galo A Goig, Fabrizio Menardo, Zubeida Salaam-Dreyer, Anzaan Dippenaar, Elizabeth M Streicher, Johnny Daniels, Anja Reuter, Sonia Borrell, Miriam Reinhard, Anna Doetsch, Christian Beisel, Robin M Warren, Helen Cox, Sebastien Gagneux
Journal: The Lancet Microbe (2023)

Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitness cost can be mitigated by compensatory mutations; however, the role of compensatory evolution in clinical settings is less clear. We assessed whether compensatory evolution was associated with increased transmission of rifampicin-resistant tuberculosis in Khayelitsha, Cape Town, South Africa.